Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug MK-4716 targets KRAS cancers in early trial

NCT ID NCT07247110

Recruiting now Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 2 times

Summary

This early-stage trial is testing an experimental drug called MK-4716, alone or combined with other cancer drugs, in people with advanced solid tumors that have a KRAS mutation. The main goal is to see if the drug is safe and tolerable. About 250 participants will be enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
MK-4716 (an experimental drug), pembrolizumab (Keytruda), and cetuximab
What this could lead to
If successful, this could point toward a new treatment option for people with advanced cancers that have a KRAS mutation.
What could go wrong
This is an early Phase 1 trial with only 250 participants, so it is primarily testing safety. The drug may not work or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALIGNANT NEOPLASM

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Asan Medical Center ( Site 0502)

    RECRUITING

    Seoul, 05505, South Korea

  • Blacktown Hospital ( Site 0455)

    RECRUITING

    Sydney, New South Wales, 2148, Australia

  • Bradfordhill ( Site 0102)

    RECRUITING

    Santiago, Region M. de Santiago, 8420383, Chile

  • Centre Hospitalier de l'Université de Montréal ( Site 0003)

    RECRUITING

    Montreal, Quebec, H2X 0A9, Canada

  • Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0002)

    RECRUITING

    Québec, Quebec, G1J 1Z4, Canada

  • FALP-UIDO ( Site 0101)

    RECRUITING

    Santiago, Region M. de Santiago, 7500921, Chile

  • Hospital Clinic de Barcelona ( Site 0362)

    RECRUITING

    Barcelona, 08036, Spain

  • Hospital General Universitari Vall d Hebron ( Site 0360)

    RECRUITING

    Barcelona, 08035, Spain

  • Hospital Universitario Fundacion Jimenez Diaz ( Site 0361)

    RECRUITING

    Madrid, 28040, Spain

  • Monash Health ( Site 0452)

    RECRUITING

    Clayton, Victoria, 3168, Australia

  • NEXT Oncology ( Site 0051)

    RECRUITING

    Irving, Texas, 75039, United States

  • NEXT Virginia ( Site 0054)

    RECRUITING

    Fairfax, Virginia, 22031, United States

  • One Clinical Research ( Site 0454)

    RECRUITING

    Nedlands, Western Australia, 6009, Australia

  • Pontificia Universidad Catolica de Chile-CICUC ( Site 0103)

    RECRUITING

    Santiago, Region M. de Santiago, 8330073, Chile

  • Princess Margaret Cancer Centre ( Site 0001)

    RECRUITING

    Toronto, Ontario, M5G 2M9, Canada

  • Rabin Medical Center ( Site 0253)

    RECRUITING

    Petah Tikva, 4941492, Israel

  • Rambam Health Care Campus ( Site 0252)

    RECRUITING

    Haifa, 3109601, Israel

  • Rutgers Cancer Institute of New Jersey ( Site 0052)

    RECRUITING

    New Brunswick, New Jersey, 08903, United States

  • Seoul National University Hospital ( Site 0501)

    RECRUITING

    Seoul, 03080, South Korea

  • Sheba Medical Center ( Site 0251)

    RECRUITING

    Ramat Gan, 5265601, Israel

  • The Alfred Hospital ( Site 0453)

    RECRUITING

    Melbourne, Victoria, 3004, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.